

New York Pharma Forum October 2018 Program

Date: Thursday, October 25, 2018

Topic: Exploring New Opportunities with Chinese Biopharma:
Deal-making and Investment

Recent developments in China around biotech and biopharma will have far-reaching impacts on the global pharmaceutical industry. With deal making, investment, and other partnerships on the rise, companies will need to adjust and develop new strategies to deal with China. This program will bring together industry analysts, consultants, as well as senior executives from Chinese pharma to discuss the opportunities, challenges, and strategies for engaging with China and the Chinese market.

Speakers:

Mr. William Burkoth, Executive Director, Pfizer Ventures

Dr. Lars E. Birgeron, President & CEO, Adlai Nortye USA

Dr. James T. Lee, Associate Principal, Defined Health

Dr. Andy Li, Founding Partner, BioSense

Dr. Anjiang (Vincent) Liu, Deputy General Manager of Strategic Product Development Center, Fosun Pharma

Dr. Sam Murphy, VP and Head of International Business Development, Shenzhen Salubris Pharmaceuticals Co Ltd. and Salubris Biotherapeutics Inc.

Moderator:

Mr. Joshua L. Berlin, Executive Director & Editor, New Ventures, BioCentury Inc.